Burzynski Research Institute, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BZYR research report →
Price Chart
About the company
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name.
- CEO
- Stanislaw R. Burzynski
- IPO
- 1997
- Employees
- 1
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on BZYR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.18M
- P/E
- -0.93
- PEG
- -0.07
- P/S
- 0.00
- P/B
- -17.57
- EV/EBITDA
- -0.92
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2073.54%
- ROIC
- 1911.08%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,386,207
- Net Income
- $-1,386,207-3.8%
- EPS
- $-0.01-2.9%
- OCF Growth
- +25.8%
- FCF Growth
- +25.8%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- 0.41
- RSI (14)
- 72
- Avg Volume
- 9.53K
No earnings-call transcripts are available for BZYR yet.
- Free Float
- 19.0%
- Shares Outstanding
- 131.45M
- Float Shares
- 24.97M
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Comerica Inc /New/ | 29.00K | ▲ 29.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 21 | Szopa-Paszkowiak Monika | other | 0 |
| Jul 3, 13 | Schiff Frederick Richard | other | 0 |
| Feb 29, 12 | Janicki Tomasz | other | 0 |
| Feb 29, 12 | Goscianski Patryk | other | 0 |
| Feb 29, 12 | Burzynski Gregory | other | 0 |
| Feb 29, 12 | Driscoll Michael | other | 0 |
| Feb 29, 12 | Hazlewood Carlton | other | 0 |
| Feb 29, 12 | Burzynski Barbara | other | 0 |
| Feb 29, 12 | Burzynski Barbara | other | 0 |
| Feb 29, 12 | Burzynski Stanislaw | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BZYR coverage
Recent articles, reports, and earnings notes.
No research on BZYR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BZYR report →